Reducing Myocardial Infarct Size: Challenges and Future Opportunities

Overview

Journal Heart

Date 2015 Dec 18

PMID 26674987

Citations 113

Authors

Heerajnarain Bulluck

Derek M Yellon

Derek J Hausenloy

Affiliations

Soon will be listed here.

Abstract

Despite prompt reperfusion by primary percutaneous coronary intervention (PPCI), the mortality and morbidity of patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) remain significant with 9% death and 10% heart failure at 1 year. In these patients, one important neglected therapeutic target is 'myocardial reperfusion injury', a term given to the cardiomyocyte death and microvascular dysfunction which occurs on reperfusing ischaemic myocardium. A number of cardioprotective therapies (both mechanical and pharmacological), which are known to target myocardial reperfusion injury, have been shown to reduce myocardial infarct (MI) size in small proof-of-concept clinical studies-however, being able to demonstrate improved clinical outcomes has been elusive. In this article, we review the challenges facing clinical cardioprotection research, and highlight future therapies for reducing MI size and preventing heart failure in patients presenting with STEMI at risk of myocardial reperfusion injury.

Citing Articles

ECG data analysis to determine ST-segment elevation myocardial infarction and infarction territory type: an integrative approach of artificial intelligence and clinical guidelines.

Kim J, Shon B, Kim S, Cho J, Seo J, Jang S Front Physiol. 2024; 15:1462847.

PMID: 39434722 PMC: 11491539. DOI: 10.3389/fphys.2024.1462847.

Identification of key genes associated with acute myocardial infarction using WGCNA and two-sample mendelian randomization study.

Yang X, Huang Y, Tang D, Yue L PLoS One. 2024; 19(7):e0305532.

PMID: 39024234 PMC: 11257238. DOI: 10.1371/journal.pone.0305532.

Cardiac-derived extracellular vesicles improve mitochondrial function to protect the heart against ischemia/reperfusion injury by delivering ATP5a1.

Liu X, Meng Q, Shi S, Geng X, Wang E, Li Y J Nanobiotechnology. 2024; 22(1):385.

PMID: 38951822 PMC: 11218245. DOI: 10.1186/s12951-024-02618-x.

Bridging gaps in automated acute myocardial infarction detection between high-income and low-income countries.

Chiou N, Koyejo S, Ngaruiya C PLOS Glob Public Health. 2024; 4(6):e0003240.

PMID: 38941326 PMC: 11213339. DOI: 10.1371/journal.pgph.0003240.

Pharmacological inhibition of RUNX1 reduces infarct size after acute myocardial infarction in rats and underlying mechanism revealed by proteomics implicates repressed cathepsin levels.

Chen H, Wang S, Zhang X, Hua X, Liu M, Wang Y Funct Integr Genomics. 2024; 24(3):113.

PMID: 38862712 PMC: 11166773. DOI: 10.1007/s10142-024-01391-2.

References

Atar D, Arheden H, Berdeaux A, Bonnet J, Carlsson M, Clemmensen P . Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J. 2014; 36(2):112-9. DOI: 10.1093/eurheartj/ehu331. View

Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T . Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370(9597):1483-93. DOI: 10.1016/S0140-6736(07)61634-1. View

Yellon D, Hausenloy D . Myocardial reperfusion injury. N Engl J Med. 2007; 357(11):1121-35. DOI: 10.1056/NEJMra071667. View

Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N . Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008; 359(5):473-81. DOI: 10.1056/NEJMoa071142. View

Timmers L, Henriques J, de Kleijn D, DeVries J, Kemperman H, Steendijk P . Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009; 53(6):501-10. DOI: 10.1016/j.jacc.2008.10.033. View

Hausenloy D, Yellon D . GLP-1 therapy: beyond glucose control. Circ Heart Fail. 2009; 1(3):147-9. DOI: 10.1161/CIRCHEARTFAILURE.108.810887. View

Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M . Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv. 2010; 3(1):49-55. DOI: 10.1016/j.jcin.2009.10.015. View

Botker H, Kharbanda R, Schmidt M, Bottcher M, Kaltoft A, Terkelsen C . Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010; 375(9716):727-34. DOI: 10.1016/S0140-6736(09)62001-8. View

Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I . Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010; 55(12):1200-1205. DOI: 10.1016/j.jacc.2009.10.052. View

10.

Larose E, Rodes-Cabau J, Pibarot P, Rinfret S, Proulx G, Nguyen C . Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular.... J Am Coll Cardiol. 2010; 55(22):2459-69. DOI: 10.1016/j.jacc.2010.02.033. View

11.

Sorensson P, Saleh N, Bouvier F, Bohm F, Settergren M, Caidahl K . Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart. 2010; 96(21):1710-5. DOI: 10.1136/hrt.2010.199430. View

12.

Munk K, Andersen N, Schmidt M, Nielsen S, Terkelsen C, Sloth E . Remote Ischemic Conditioning in Patients With Myocardial Infarction Treated With Primary Angioplasty: Impact on Left Ventricular Function Assessed by Comprehensive Echocardiography and Gated Single-Photon Emission CT. Circ Cardiovasc Imaging. 2010; 3(6):656-62. DOI: 10.1161/CIRCIMAGING.110.957340. View

13.

Wei M, Xin P, Li S, Tao J, Li Y, Li J . Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ Res. 2011; 108(10):1220-5. DOI: 10.1161/CIRCRESAHA.110.236190. View

14.

Longacre L, Kloner R, Arai A, Baines C, Bolli R, Braunwald E . New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation. 2011; 124(10):1172-9. PMC: 3709973. DOI: 10.1161/CIRCULATIONAHA.111.032698. View

15.

Lonborg J, Kelbaek H, Vejlstrup N, Botker H, Kim W, Holmvang L . Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012; 5(2):288-95. DOI: 10.1161/CIRCINTERVENTIONS.112.968388. View

16.

Lonborg J, Vejlstrup N, Kelbaek H, Botker H, Kim W, Mathiasen A . Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2011; 33(12):1491-9. DOI: 10.1093/eurheartj/ehr309. View

17.

Hausenloy D, Botker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G . Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013; 98(1):7-27. DOI: 10.1093/cvr/cvt004. View

18.

Chakrabarti A, Feeney K, Abueg C, Brown D, Czyz E, Tendera M . Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy.... Am Heart J. 2013; 165(4):509-514.e7. DOI: 10.1016/j.ahj.2012.12.008. View

19.

Hausenloy D . Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science). Curr Pharm Des. 2012; 19(25):4544-63. DOI: 10.2174/1381612811319250004. View

20.

Woo J, Kim W, Ha S, Kim J, Kim S, Kim W . Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013; 33(9):2252-60. DOI: 10.1161/ATVBAHA.113.301586. View